What a Low Tumor Mutation Burden Means for Your Cancer

A low tumor mutation burden means your cancer has relatively few DNA mutations per stretch of its genome, and that has real implications for which treatments are most likely to work. In particular, immunotherapy drugs called checkpoint inhibitors tend to be less effective when mutation counts are low, because fewer mutations generally mean fewer abnormal proteins for your immune system to recognize and attack. But “low TMB” is far from a dead end. Chemotherapy, targeted therapies, radiation, and emerging combination approaches all remain on the table, and in some cases work better when TMB is low.

What TMB Actually Measures

Tumor mutation burden counts the number of acquired (somatic) mutations in the DNA of cancer cells. It is usually reported as mutations per megabase of DNA sequenced. The number varies enormously depending on cancer type, the specific tumor, and even the test used to measure it.¹ A “low” TMB generally means fewer than 10 mutations per megabase, which is the threshold the FDA used when approving the checkpoint inhibitor pembrolizumab for TMB-high solid tumors. Some research groups use different cutoffs, and the honest reality is that there is no universally agreed-upon number that cleanly separates “low” from “high” across every cancer type.

Why do mutations matter for treatment decisions? Each somatic mutation can produce slightly altered proteins called neoantigens on the surface of cancer cells. These abnormal proteins act like flags that the immune system can learn to spot. The more mutations a tumor carries, the more potential flags it displays, and the better the odds that immune-based therapies will help your body mount an effective attack.² When TMB is low, there are simply fewer of those flags, which makes it harder for checkpoint inhibitors to do their job.

Why Immunotherapy Is Less Likely to Work

The connection between high TMB and better immunotherapy responses is well documented. A large pooled analysis of over 100,000 cancer patients found that people with high TMB who received immunotherapy had substantially better overall survival and progression-free survival compared to those with low TMB.³ In the CheckMate 568 trial for advanced lung cancer, the objective response rate was about 44% in patients with 10 or more mutations per megabase compared to just 12% in those below that threshold. Progression-free survival was also markedly longer in the higher-TMB group.⁴

But the picture gets more complicated when you look at different cancer types individually. Research categorizing cancers into “high-TMB” types (like melanoma and lung cancer) and “low-TMB” types (like prostate and ovarian cancer) found that a high TMB score predicted a better immunotherapy response only in the cancer types that tend to have high mutation counts overall. In cancer types that generally carry few mutations, having a relatively higher TMB within that range did not improve response rates and in some cases was associated with a slightly worse outcome.⁵ This suggests that TMB is not a one-size-fits-all predictor; the type of cancer matters just as much as the raw number.

Which Cancers Tend to Have Low TMB

Some cancers almost always fall in the low-TMB category. Multi-omics analysis has found that cancer types with less than 1% of cases qualifying as TMB-high include thyroid cancer, prostate cancer, clear-cell kidney cancer, papillary kidney cancer, acute myeloid leukemia, ovarian cancer, pheochromocytoma/paraganglioma, and thymoma.⁶ By contrast, colorectal cancer, melanoma, and endometrial cancer can range from very low to very high TMB values, sometimes spanning from 2 to 400 mutations per megabase. Prostate, breast, myeloma, and serous ovarian cancers cluster in a much narrower and lower range.⁷

Even within a single cancer type, subtypes matter. In breast cancer, triple-negative tumors carry significantly higher TMB than non-triple-negative tumors and are more likely to cross into TMB-high territory.⁶ If you have a cancer type that is generally low-TMB, your oncologist will factor that into which treatments are prioritized from the start.

Low TMB Does Not Mean Fewer Treatment Options

One of the biggest misconceptions patients face after learning they have low TMB is that it limits their treatment options. It limits one specific category of treatment, checkpoint inhibitor immunotherapy, and even that limitation has exceptions. Chemotherapy and targeted therapy remain the backbone of treatment for many low-TMB cancers, and in some situations low TMB is actually associated with better outcomes from those treatments.

A study of non-small cell lung cancer patients carrying EGFR mutations found that those with low TMB who received targeted EGFR drugs had dramatically longer progression-free survival than patients with higher TMB: roughly 16 months compared to 9 months for intermediate TMB and about 7 months for high TMB.⁸ The likely explanation is that a tumor with fewer background mutations is more genetically “focused” on its driver mutation, making it more vulnerable to a drug designed to block that specific target. This is genuinely good news if your tumor has a known driver mutation and a low TMB.

Standard chemotherapy also appears unaffected by TMB in most scenarios. A study examining breast, lung, and gastrointestinal cancers found no significant difference in progression-free survival between patients with TMB below or above 10 mutations per megabase when treated with cytotoxic chemotherapy.⁹ In lung cancer specifically, one study found that low-TMB patients actually had longer progression-free survival on first-line chemotherapy compared to those with higher TMB.¹⁰ So while high TMB may steer treatment toward immunotherapy, low TMB does not leave you worse off when it comes to chemotherapy or targeted drugs.

When Low-TMB Tumors Still Respond to Immunotherapy

The low-TMB label is not an absolute bar to immunotherapy benefit. Case reports and small series document responses in tumors that would seem to have everything working against them. In one report, three patients with advanced intrahepatic bile duct cancer had TMB levels of 0.98, 1.2, and 3.8 mutations per megabase, along with microsatellite stability, proficient mismatch repair, and essentially no PD-L1 expression. All three responded when stereotactic radiation was combined with a checkpoint inhibitor, with one patient achieving a complete response lasting 11 months.¹¹

These cases are anecdotal, and they do not change the overall statistics. But they illustrate that other features of the tumor and its environment can influence immune response. A tumor that is “cold” in terms of mutation count might still become vulnerable if the microenvironment is altered, for example by radiation or other agents that provoke immune recognition through different pathways.

TMB Is Prognostic Too, Not Just Predictive

There is an important distinction that often gets lost in patient conversations. TMB can act as both a predictive biomarker (helping forecast whether a specific treatment will work) and a prognostic biomarker (reflecting the overall aggressiveness or trajectory of the disease independent of treatment). These two roles sometimes pull in opposite directions.

In several cancer types, patients with lower TMB have been found to have longer overall survival regardless of treatment. This pattern has been observed in lung cancer, colon cancer, prostate cancer, and head and neck cancer. However, in bladder cancer, the relationship flips: higher TMB is associated with better survival even outside the immunotherapy context.¹² This inconsistency across cancer types means that a low TMB result might carry a different prognostic implication depending on your diagnosis. In some cancers it suggests a less aggressive disease course, while in others it tells you less than you might hope.

The Microsatellite Instability Connection

If you have heard of microsatellite instability (MSI), you may be wondering how it relates to TMB. The two biomarkers overlap considerably but are not identical. MSI-high tumors have defects in DNA repair that cause them to accumulate mutations rapidly, so they almost always have high TMB as well. In a study of nearly 6,000 colorectal cancers, all but one MSI-high case also qualified as TMB-high.¹³

The more interesting finding, however, is what TMB testing catches that MSI testing misses. In that same colorectal cancer dataset, about 3% of microsatellite-stable (MSS) tumors still had high TMB. Those patients would have been excluded from immunotherapy based on MSI testing alone, but their high mutation counts suggest they might respond to checkpoint inhibitors. Adding TMB testing to the picture increased the pool of potentially eligible patients by more than 50%.¹³ For patients who are MSS and low-TMB, immunotherapy remains a harder sell, but these findings reinforce why testing for both markers gives a more complete picture.

Combination Strategies for “Cold” Tumors

Oncologists increasingly refer to low-TMB, immune-quiet tumors as “cold” tumors, in contrast to the “hot” tumors that are rich in immune-cell infiltration and more responsive to checkpoint inhibitors.¹⁴ A major area of active research is figuring out how to convert cold tumors into hot ones. The strategies under investigation aim to provoke the immune system into noticing a tumor it has been ignoring.

Radiation therapy and chemotherapy can trigger a form of cancer-cell death that releases tumor proteins into the surrounding tissue, essentially training nearby immune cells to recognize the cancer. When paired with checkpoint inhibitors, these approaches can reshape the tumor’s local environment and sometimes produce responses in tumors that would not have responded to immunotherapy alone.¹⁵ In triple-negative breast cancer, combining checkpoint inhibitors with chemotherapy has pushed pathological complete response rates above 50% in clinical trials, though the presence of cold-tumor features like insufficient T-cell infiltration remains a barrier to further improvement.¹⁶

Emerging agents being studied in this space include STING agonists (drugs that activate an innate immune-signaling pathway), tumor vaccines, and drugs that normalize the blood vessels feeding a tumor to allow immune cells better access. Many of these are still in clinical trials, but the underlying logic is sound: if the problem is that the immune system cannot see or reach the tumor, then therapies that increase visibility or access could complement checkpoint blockade.¹⁷

Measurement Matters More Than You Might Think

The TMB number on your report is not as rock-solid as it looks. Different gene-panel tests measure different slices of the genome, and small panels are notoriously imprecise at estimating TMB in the low-to-moderate range. Research suggests that panels covering between 1.5 and 3 megabases of DNA strike the best balance between cost and accuracy, while smaller panels tend to deliver imprecise TMB estimates for exactly the range where most patients fall (0 to 30 mutations per megabase).¹⁸ A comprehensive comparison of 38 different panel methods found that technical settings, like how aggressively the test filters for low-frequency mutations, substantially affected TMB accuracy. Most panels used a 5% variant-frequency cutoff, but panels with more aggressive (lower) cutoffs tended to perform worse.¹⁹

What this means for you: a TMB score of 8 on one test and 12 on another could reflect the same underlying biology, placing you on different sides of the 10-mutation cutoff depending on the platform. If your treatment hinges on whether your TMB is “high” or “low,” it is reasonable to ask your oncology team which panel was used and how confident they are in the result near the boundary. Standardization is an acknowledged problem the field is still working to solve.¹

Blood-Based TMB Testing

Most TMB testing requires a tissue biopsy, but liquid biopsy (a blood draw that captures fragments of tumor DNA circulating in the bloodstream) is emerging as an alternative. When there is enough tumor-derived DNA in the blood, the agreement between blood-based and tissue-based TMB is strong: one study found a correlation of 0.74 and greater than 80% sensitivity for detecting TMB-high status when the plasma tumor fraction was at least 1%.²⁰ The challenge is that not all tumors shed enough DNA into the blood. For patients whose cancers are hard to biopsy or who have had prior surgery, liquid biopsy could be valuable, but the technology still needs further validation before it can fully replace tissue testing.²¹

Pediatric Cancers and Very Low Mutation Counts

Childhood cancers almost universally have very low TMB. Whole-genome sequencing across a broad range of pediatric tumors has found mutation rates more than tenfold lower than in adult cancers, averaging between 0.02 and 0.49 mutations per megabase compared to 0.13 to 1.8 in adults.²² Pediatric tumors also look fundamentally different from adult tumors in how they develop. Rather than accumulating mutations from decades of environmental exposure, they tend to be driven by structural DNA changes like gene fusions, copy number alterations, and inherited mutations in cancer-predisposition genes.²³

There is a notable exception: children who inherit biallelic mismatch repair deficiency develop tumors with dramatically elevated mutation rates, sometimes 100 to 1,000 times higher than other pediatric cancers, exceeding even many adult tumor types.²² These rare cases can be candidates for immunotherapy. For the vast majority of childhood cancers, though, checkpoint inhibitors are not a frontline approach, and treatment strategies rely on chemotherapy, surgery, and radiation tailored to the specific tumor biology.

Can TMB Change Over Time

Your tumor’s TMB is not necessarily fixed. Treatment itself can alter the mutational landscape of a cancer. Chemotherapy and radiation damage DNA, and surviving cancer cells may accumulate new mutations as they repair that damage. Some researchers have proposed re-testing TMB after chemotherapy, especially in tumors that started with low counts, to see if they have crossed into a range where immunotherapy might become useful. However, the evidence so far is cautious: while TMB can increase after treatment, the bump usually stays below the 10-mutation threshold that current guidelines use for immunotherapy eligibility.²⁴ Re-biopsy for TMB reassessment is not yet standard practice, but it is something researchers are actively investigating, particularly for patients whose initial low TMB left immunotherapy off the table.

The broader takeaway is that TMB is a snapshot, not a permanent label. The interplay between your cancer’s biology, the treatments you receive, and the tumor’s evolving genetics means that the options available to you can shift over the course of your treatment. An engaged conversation with your oncologist about the full range of biomarkers, not just TMB, is the most practical thing you can do to make sure no reasonable avenue gets overlooked.

1
PubMed Central. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
2
PubMed Central. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives
3
PubMed Central. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
4
PubMed Central. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
5
PubMed Central. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
6
PubMed Central. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data
7
Journal of Clinical Oncology. Distributional range of tumor mutational burden (TMB) across multiple cancer types emphasizing the importance of different cutoff values in different tumor types for clinical interpretation
8
Frontiers in Oncology. Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
9
PubMed Central. Tumor mutational burden is not predictive of cytotoxic chemotherapy response
10
PubMed. Tumor mutational burden and efficacy of chemotherapy in lung cancer
11
Journal for ImmunoTherapy of Cancer. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
12
Clinical Cancer Research. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
13
PubMed Central. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
14
PubMed Central. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
15
Frontiers in Immunology. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
16
PubMed. The “Cold Tumor” to “Hot Tumor” transformation strategy for triple-negative breast cancer: from mechanism to clinical translation
17
PubMed Central. Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation
18
PubMed. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis
19
npj Precision Oncology. Enhancing the quality of panel-based tumor mutation burden assessment: a comprehensive study of real-world and in-silico outcomes
20
PubMed Central. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed
21
PubMed Central. Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
22
PubMed Central. Developmental origins shape the pediatric cancer genome
23
PubMed Central. The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
24
ESMO Open. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure